Literature DB >> 11872303

Prostate brachytherapy postimplant dosimetry: a comparison of prostate quadrants.

Sabeena Sidhu1, W James Morris, Ingrid Spadinger, Mira Keyes, Michelle Hilts, Robert Harrison, Karl Otto, Michael McKenzie, Alexander Agranovich.   

Abstract

PURPOSE: To investigate postimplant dosimetry for different regions of the prostate gland in patients treated with transperineal 125Iodine brachytherapy implants for low- and intermediate-risk prostate cancer. METHODS AND MATERIALS: Two hundred eighty-four patients treated with permanent interstitial prostate brachytherapy comprised the study population. A nonuniform, urethral-sparing algorithm was used to plan all patients. Prostate contours were outlined on postimplant CT images. Prostate volumes were then divided into four quadrants: anterior-superior quadrant (ASQ), posterior-superior quadrant (PSQ), anterior-inferior quadrant (AIQ), and posterior-inferior quadrant (PIQ). Dose-volume histograms (DVHs) were calculated for the whole prostate and each quadrant.
RESULTS: The mean postimplant V(100) +/- 95% confidence (the percent prostate volume encompassed within the isodose surface comprising the prescription dose = 144 Gy) for the ASQ was 78.5 +/- 1.9, which was significantly lower than that of the PSQ, AIQ, and PIQ in which the V(100) plus minus 95% confidence values were 94.9 +/- 0.8, 92.6 +/- 1.2, and 98.7 +/- 0.3, respectively. The mean V(100) +/- 95% confidence for the whole prostate was 90.4 +/- 0.8. Mean values for V(150) and D(90) (the minimum dose in Gy received by 90% of the target volume) for the four quadrants and the whole prostate showed similar results.
CONCLUSIONS: Underdosed areas of the planning target volume (PTV), if present, were largely confined to the ASQ, which received a significantly lower dose, on average, compared to the other three quadrants of the prostate.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11872303     DOI: 10.1016/s0360-3016(01)02672-4

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  8 in total

1.  Permanent prostate brachytherapy: the significance of postimplant dosimetry.

Authors:  W Robert Lee
Journal:  Rev Urol       Date:  2004

2.  Favorable long-term toxicity for salvage low-dose rate prostate brachytherapy for recurrent prostate cancer after external beam radiotherapy from a phase II prospective trial (NRG Oncology/RTOG 0526).

Authors:  Randall J Brenneman; Edward Soffen; Hiram A Gay; Peter F Orio; John P Christodouleas; John C Baumann; Brian C Baumann
Journal:  Transl Androl Urol       Date:  2019-07

3.  Comparison of post-implant dosimetrics between intraoperatively built custom-linked seeds and loose seeds by sector analysis at 24 hours and 1 month for localized prostate cancer.

Authors:  Eiichiro Okazaki; Katsuyuki Kuratsukuri; Tomohiro Nishikawa; Tomoaki Tanaka; Mai Sakagami; Keiko Shibuya
Journal:  J Contemp Brachytherapy       Date:  2020-08-21

4.  Multisector dosimetry in the immediate post-implant period: significant under dosage of the prostate base.

Authors:  Austin N Kirschner; Vythialingam Sathiaseelan; Yunkai Zhang; James David; John A Kalapurakal
Journal:  J Contemp Brachytherapy       Date:  2014-04-03

5.  Pre-plan parameters predict post-implant D90 ≥ 140 Gy for (125)I permanent prostate implants.

Authors:  Jes Alexander; Vivian Weinberg; Alexander R Gottschalk; I-Chow Joe Hsu; Katsuto Shinohara; Mack Roach
Journal:  J Contemp Brachytherapy       Date:  2014-06-03

6.  Comparison of implant quality between intraoperatively built custom-linked seeds and loose seeds in permanent prostate brachytherapy using sector analysis.

Authors:  Norihisa Katayama; Mitsuhiro Takemoto; Atsushi Takamoto; Hiroki Ihara; Kuniaki Katsui; Shin Ebara; Yasutomo Nasu; Susumu Kanazawa
Journal:  J Radiat Res       Date:  2016-03-13       Impact factor: 2.724

7.  Correlations of post-implant regional dosimetric parameters at 24 hours and one month, with clinical results of low-dose-rate brachytherapy for localized prostate cancer.

Authors:  Eiichiro Okazaki; Katsuyuki Kuratsukuri; Kentaro Ishii; Tomoaki Tanaka; Ryo Ogino; Tomohiro Nishikawa; Hideyuki Morimoto; Masako Hosono; Yukio Miki
Journal:  J Contemp Brachytherapy       Date:  2017-12-30

8.  Tumor burden and location as prognostic factors in patients treated by iodine seed implant brachytherapy for localized prostate cancers.

Authors:  Claire Meynard; Andres Huertas; Charles Dariane; Sandra Toublanc; Quentin Dubourg; Saik Urien; Marc-Olivier Timsit; Arnaud Méjean; Nicolas Thiounn; Philippe Giraud
Journal:  Radiat Oncol       Date:  2019-12-31       Impact factor: 3.481

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.